Andere talen Protagonist Therapeutics, Inc.

Aandelen

PTGX

US74366E1029

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
26,85 ^USD	+0,90%		+2,83%	+17,10%

03/04	Insider van Protagonist Therapeutics verkocht aandelen ter waarde van $707.750, volgens een recent SEC-document	MT
26/03	Protagonist Therapeutics, Inc. Geeft een update over de inschrijvingen van VERIFY-patiënten en de timing van de belangrijkste gegevens	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Protagonist Therapeutics Insider Sold Shares Worth $707,750, According to a Recent SEC Filing	03/04
Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data	27/03
Protagonist Therapeutics, Inc. Provides Update on Verify Patient Enrollment and Timing of Top-Line Data	26/03
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda	18/03
Protagonist Therapeutics' Potential Plaque Psoriasis Drug Shows High Skin Clearance Rates in Phase 2B Study	11/03
Protagonist Therapeutics, Inc. Announces Late-Breaking Presentation At the American Academy of Dermatology 2024 Annual Meeting with Positive Results from the Phase 2B Frontier 2 Long-Term Extension Study Evaluating JNJ-2113, the First and Only Investigational Targeted Oral Peptide Designed to Block the IL-23 Receptor, for Adult Patients with Moderate-To-Severe Plaque Psoriasis	11/03
Protagonist Therapeutics Insider Sold Shares Worth $948,600, According to a Recent SEC Filing	04/03
Protagonist Therapeutics Insider Sold Shares Worth $406,637, According to a Recent SEC Filing	04/03
Protagonist Therapeutics Insider Sold Shares Worth $764,365, According to a Recent SEC Filing	04/03
Protagonist Therapeutics: Q4 Earnings Snapshot	27/02
Protagonist Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Protagonist Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/02
Protagonist Therapeutics Shares Rise 5.6% on Licensing Deal With Takeda	01/02
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset	31/01
Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024	30/01
Protagonist Therapeutics Insider Sold Shares Worth $1,506,000, According to a Recent SEC Filing	15/12
Protagonist Therapeutics Earns $10 Million Milestone Payment in Ulcerative Colitis Trial	13/12
Protagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety Signals	13/12
Protagonist Therapeutics, Inc. Announces $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis	13/12
Protagonist Announces Two New Phase 3 ICONIC Studies in Psoriasis Evaluating JNJ-2113 in Head-to-Head Comparisons with Deucravacitinib	28/11

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Protagonist Therapeutics, Inc.

Aandelen

PTGX

US74366E1029

Andere talen

Filters